

# Development of a novel small molecule targeting ASK1 for the treatment of Parkinson's disease

Naason Science Inc.



NEUROLOGY	Candidate
Product Type	Small molecules
Indication	Parkinson's disease
Target	ASK1 (Apoptosis signal-regulating kinase 1)
MoA(Mechanism of Action)	Inhibition of ASK1 (ASK1 inhibitor) → p38 inhibition → Anti-neuroinflammation and neuroprotection → Therapy for PD
Competitiveness	<ul style="list-style-type: none"> <li>• Target: ASK1 (upstream regulator of p38/JNK MAPK under oxidative stress)</li> <li>• Mechanism: Inhibits ASK1 to block neuroinflammation and dopaminergic neuron loss</li> <li>• Therapeutic Strategy: Disease-modifying, not just symptomatic</li> <li>• Strength: Novel mechanism with strong preclinical efficacy</li> <li>• Potential: First-in-class drug candidate for Parkinson's disease</li> </ul>
Development Stage	Candidate
Route of Administration	Oral administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*